Oct 02 2018 Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels View
Sep 18 2018 Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder View
Aug 09 2018 Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms View
Jun 27 2018 Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder View
Apr 03 2018 Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer View
Jan 17 2018 Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System View
Jan 09 2018 Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms View
Oct 27 2017 Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms View
Jun 28 2017 Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program View
